Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28350744 | 0.82 | EPHX1 (0.51) | EPHX1TRPM8TRPA1ALDH1A1 | |
| SCHEMBL12972998 | 0.82 | SLC6A12 (0.48) | EPHX1TRPM8TRPA1SLC1A2MEN1 | |
| SCHEMBL11212023 | 0.81 | ALDH1A1 (0.30) | ALDH1A1TDP1 | |
| SCHEMBL3264640 | 0.79 | TRPM8 (0.43) | EPHX1TRPM8TRPA1 | |
| SCHEMBL3264638 | 0.79 | TRPM8 (0.43) | EPHX1TRPM8TRPA1 | |
| SCHEMBL12658594 | 0.78 | TRPM8 (0.36) | EPHX1TRPM8TRPA1SLC1A2MEN1 | |
| SCHEMBL14392077 | 0.77 | EPHX1 (0.36) | EPHX1TRPM8TRPA1SLC1A2MEN1 | |
| SCHEMBL10121240 | 0.72 | EPHX2 (0.41) | EPHX1ALDH1A1 | |
| SCHEMBL11960304 | 0.70 | — | — | |
| SCHEMBL12633783 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | BUSHELL SIMON (US) | 2014-10-23 | — | — | US | disclosed |
| US-20130252883-A1 | Macrocycles and Their Uses | NOVARTIS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8476224-B2 | Macrocycles and their uses | NOVARTIS AG (US) | 2013-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252883-A1 | Macrocycles and Their Uses | MRPL21, CLPP, MLEC | EPHX1 4026/4885TRPM8 3429/4885TRPA1 3597/4885 |
| US-20140315790-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, GOT2 | EPHX1 2553/4885TRPM8 1383/4885TRPA1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.